TFF raises millions more to develop new respiratory drugs

TFF Pharmaceuticals Inc. has millions more in venture capital to fund its quest for better drugs related to respiratory problems. The year-old Austin startup announced May 30 that it raised another $8.2 million more via an offering of series A preferred stock. It comes 13 months after TFF collected $14 million from more than 200 investors. TFF is developing a way to increase the water solubility of drugs, allowing them to b e delivered with an inhaler and making them easier to absorb. About 40 percent…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news